Who Should Receive Immunotherapy for Advanced Gastroesophageal Cancer?
Curr Treat Options Oncol
; 25(4): 496-509, 2024 04.
Article
in En
| MEDLINE
| ID: mdl-38372852
ABSTRACT
OPINION STATEMENT This paper shines a light on the exciting progress being made in using immunotherapy to treat advanced gastroesophageal cancers. The positive results from trials using drugs like Pembrolizumab and Nivolumab are certainly encouraging and open new possibilities for treating this challenging disease. However, it is clear that we still have a lot to learn about how to predict which patients will benefit most from these treatments. The exploration of combining therapies and using machine learning to guide treatment shows promise. Moving forward, it is crucial that researchers and healthcare professionals continue to work together, sharing knowledge and findings to continue the advancements in this important area.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Esophageal Neoplasms
Limits:
Humans
Language:
En
Journal:
Curr Treat Options Oncol
/
Curr. treat. options oncol
/
Current treatment options in oncology
Journal subject:
NEOPLASIAS
Year:
2024
Type:
Article
Affiliation country:
United States